Peran Antibody-Dependent Enhancement pada COVID-19

Oleh :

dr. Hendra Gunawan SpPD

Antibody-dependent enhancement pada pasien COVID-19 memberikan dampak negatif terhadap kesuksesan terapi dan vaksinasi. Antibody-dependent enhancement (ADE) merupakan fenomena yang terjadi akibat virus menginfeksi makrofag, sehingga antibodi yang seharusnya menetralisir virus justru meningkatkan kemampuan virus untuk menginfeksi sel tubuh secara spesifik dan meningkatkan replikasi virus.[1,2]

Peran ADE pada infeksi SARS-CoV-2 masih terus diteliti saat ini, termasuk perannya terhadap keparahan infeksi maupun efektivitas vaksin. Fenomena ADE sebelumnya telah dilaporkan terjadi pada infeksi virus dengue dan virus SARS-CoV. Artikel ini akan membahas ADE dan peranannya pada infeksi SARS-CoV-2.

Patofisiologi Antibody-Dependent Enhancement

(Konten ini khusus untuk dokter. Registrasi untuk baca selengkapnya)

Referensi

1.Wen J, Cheng Y, Ling R, Dai Y, Huang B, Huang W, et al. Antibody-dependent enhancement of coronavirus. International Journal of Infectious Diseases. 2020;100:483-9.
2.Taylor A, Foo S-S, Bruzzone R, Vu Dinh L, King NJC, Mahalingam S. Fc receptors in antibody-dependent enhancement of viral infections. Immunological Reviews. 2015;268(1):340-64.
3.Wang Q, Zhang L, Kuwahara K, Li L, Liu Z, Li T, et al. Immunodominant SARS Coronavirus Epitopes in Humans Elicited both Enhancing and Neutralizing Effects on Infection in Non-human Primates. ACS Infectious Diseases. 2016;2(5):361-76.
4.Lee WS, Wheatley AK, Kent SJ, DeKosky BJ. Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies. Nature Microbiology. 2020;5(10):1185-91.
5.Sridhar S, Luedtke A, Langevin E, Zhu M, Bonaparte M, Machabert T, et al. Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy. N Engl J Med. 2018;379(4):327-40.
6.Chakraborty S, Edwards K, Buzzanco AS, Memoli MJ, Sherwood R, Mallajosyula V, et al. Symptomatic SARS-CoV-2 infections display specific IgG Fc structures. medRxiv. 2020:2020.05.15.20103341.
7.Larsen MD, de Graaf EL, Sonneveld ME, Plomp HR, Linty F, Visser R, et al. Afucosylated immunoglobulin G responses are a hallmark of enveloped virus infections and show an exacerbated phenotype in COVID-19. bioRxiv. 2020:2020.05.18.099507.
8.Ho MS, Chen WJ, Chen HY, Lin SF, Wang MC, Di J, et al. Neutralizing antibody response and SARS severity. Emerg Infect Dis. 2005;11(11):1730-7.
9.Sekine T, Perez-Potti A, Rivera-Ballesteros O, Strålin K, Gorin J-B, Olsson A, et al. Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. Cell. 2020;183(1):158-68.e14.
10.Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019. Clinical Infectious Diseases. 2020;71(16):2027-34.
11.Xu X, Chen P, Wang J, Feng J, Zhou H, Li X, et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci China Life Sci. 2020;63(3):457-60.
12.Gao J, Lu G, Qi J, Li Y, Wu Y, Deng Y, et al. Structure of the fusion core and inhibition of fusion by a heptad repeat peptide derived from the S protein of Middle East respiratory syndrome coronavirus. J Virol. 2013;87(24):13134-40.
13.Wang FS, Chu FL, Jin L, Li YG, Zhang Z, Xu D, et al. Acquired but reversible loss of erythrocyte complement receptor 1 (CR1, CD35) and its longitudinal alteration in patients with severe acute respiratory syndrome. Clin Exp Immunol. 2005;139(1):112-9.
14.Ricke DO. Two Different Antibody-Dependent Enhancement (ADE) Risks for SARS-CoV-2 Antibodies. Frontiers in Immunology. 2021;12(443).
15.Tillett RL, Sevinsky JR, Hartley PD, Kerwin H, Crawford N, Gorzalski A, et al. Genomic evidence for reinfection with SARS-CoV-2: a case study. Lancet Infect Dis. 2021;21(1):52-8.
16.Honda-Okubo Y, Barnard D, Ong CH, Peng BH, Tseng CT, Petrovsky N. Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology. J Virol. 2015;89(6):2995-3007.
17.Gao Q, Bao L, Mao H, Wang L, Xu K, Yang M, et al. Development of an inactivated vaccine candidate for SARS-CoV-2. Science. 2020;369(6499):77-81.
18. Shukla R, Ramasamy V, Shanmugam RK, Ahuja R, Khanna N. Antibody-Dependent Enhancement: A Challenge for Developing a Safe Dengue Vaccine. Front Cell Infect Microbiol. 2020 Oct 22;10:572681. doi: 10.3389/fcimb.2020.572681. PMID: 33194810; PMCID: PMC7642463.